AZN Astrazeneca Plc

12,026.00

674.00 (5.94%)

25 Apr 2024 - Closed

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type	Share ISIN	Share Description
Astrazeneca Plc	LSE:AZN	London	Ordinary Share	GB0009895292	ORD SHS $0.25

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	674.00	5.94%	12,026.00	12,006.00	12,012.00	12,096.00	11,850.00	11,890.00	4,650,557	16:35:08

Industry Sector	Turnover	Profit	EPS - Basic	PE Ratio	Market Cap
Pharmaceutical Preparations	45.81B	5.96B	3.8415	31.26	186.15B

AstraZeneca Reports Positive Results of 2 Lung Cancer Trials

11/09/2017 7:51am

Dow Jones News

Astrazeneca (LSE:AZN)
Historical Stock Chart

From Apr 2019 to Apr 2024

By Ian Walker

Pharmaceutical giant AstraZeneca PLC (AZN.LN) Monday reported positive results from two trials for lung cancer treatments.

It said a Phase III Pacific trial of Imfinzi improved progression-free survival by more than 11 months compared with standard of care. AstraZeneca added that the trial continues to evaluate the other primary endpoint, overall survival.

The company also said a Phase III Flaura trial of Tagrisso reduced the risk of progression or death by more than half, with consistent benefit across all subgroups, including patients with and without brain metastases.

Tagrisso also showed median progression-free survival of 18.9 months, compared with 10.2 months for the current standard of care, AstraZeneca said.

Write to Ian Walker at ian.walker@wsj.com; @IanWalk40289749

(END) Dow Jones Newswires

September 11, 2017 02:36 ET (06:36 GMT)